ImmunoGen, Inc. [NASDAQ: IMGN] opened at $2.06 and closed at $2.05 a share within trading session on 13/06/2019. That means that the stock gained by 6.34% compared to the closing price from a day before, when the stock touched $2.18.
Between the start and the closing of the latest trading session, ImmunoGen, Inc. [NASDAQ: IMGN] had 2.4 million shares being bought and sold. In the last three months, average trading volumes hovered around 3.36M shares. During the last week, volatility in the share price was set at 7.36%, which placed the metric for the last 30 days at 7.83%. The price of the stock additionally went down to $1.76 during that period and IMGN managed to take a rebound to $12.31 in the last 52 weeks.
ImmunoGen, Inc. [NASDAQ:IMGN]: Analyst Rating and Earnings
Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. For ImmunoGen, Inc. [IMGN], the latest consensus recommendation available followed its financial results for the fiscal quarter ending in December. On average, stock market experts give IMGN an Outperform rating. Its stock price has been found in the range of 1.76 to 12.31. This is compared to its latest closing price of $2.05.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for ImmunoGen, Inc. [IMGN] is sitting at 2.40. This is compared to 1 month ago, when its average rating was 2.20.
For the quarter ending in Mar-19 ImmunoGen, Inc. [IMGN] generated $0.01 billion in sales. That’s 18.98% lower than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Fri 26 Jul (In 42 Days).
Fundamental Analysis of ImmunoGen, Inc. [IMGN]
Now let’s turn to look at profitability: with a current Operating Margin for ImmunoGen, Inc. [IMGN] sitting at -295.17.
Turning to investigate this organization’s capital structure, ImmunoGen, Inc. [IMGN] has generated a Total Debt to Total Equity ratio of 1,369.75. Similarly, its Total Debt to Total Capital is 93.20, while its Total Debt to Total Assets stands at 50.88. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 1,133.88, and its Long-Term Debt to Total Capital is 77.15. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -1.43. The Enterprise Value to Sales for this firm is now 5.06, and its Total Debt to Enterprise Value stands at 0.27. ImmunoGen, Inc. [IMGN] has a Price to Book Ratio of 65.36.
Shifting the focus to workforce efficiency, ImmunoGen, Inc. [IMGN] earns $180,561 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.18 and its Total Asset Turnover is 0.18. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.95 and its Current Ratio is 3.95. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
ImmunoGen, Inc. [IMGN] has 147.81M shares outstanding, amounting to a total market cap of $322.23M. Its stock price has been found in the range of 1.76 to 12.31. At its current price, it has moved down by -82.29% from its 52-week high, and it has moved up 23.86% from its 52-week low.
This stock’s Beta value is currently 2.27, which indicates that it is 7.36% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 49.16. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is ImmunoGen, Inc. [IMGN] a Reliable Buy?
ImmunoGen, Inc. [IMGN] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.